10-Q: Neumora Therapeutics Reports Q1 2025 Financial Results, Highlights Clinical Pipeline Progress

Neumora Therapeutics announces its Q1 2025 financial results, detailing operating expenses, liquidity, and progress in its clinical development programs, including navacaprant and NMRA-511.

Summary

• Neumora Therapeutics reported a net loss of $67.99 million for the three months ended March 31, 2025, compared to a net loss of $53.72 million for the same period in 2024.
• Research and development expenses increased to $52.15 million from $45.76 million year-over-year, primarily due to costs incurred under the Amgen Collaboration Agreement.
• General and administrative expenses rose to $18.79 million from $14.32 million, driven by higher personnel-related costs and stock-based compensation.
• The company's cash, cash equivalents, and marketable securities totaled $249.4 million as of March 31, 2025.
• Neumora believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next 12 months.
• The company expects to report topline data from the KOASTAL-3 trial in Q1 2026 and KOASTAL-2 in Q2 2026.
• Data from the Phase 1b signal-seeking study of NMRA-511 is expected around the end of 2025.
• Neumora anticipates progressing an M4 PAM into the clinic in mid-2025.
• On May 9, 2025, Neumora entered into a loan agreement with K2 HealthVentures for up to $125 million in term loans.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is progressing with its clinical trials and has secured additional funding, it also reported an increased net loss and is reliant on future capital raises.

Positives

• The company believes its current cash position is sufficient to fund operations for at least the next 12 months.
• Clinical trials for navacaprant and NMRA-511 are progressing, with expected data readouts in the near future.
• The company is advancing its M4 PAM program towards clinical trials.
• A new loan agreement provides additional financial flexibility.

Negatives

• The net loss increased compared to the same period last year.
• Operating expenses, particularly research and development, have increased.
• The company is still reliant on external funding to continue operations.

Risks

• The company is subject to risks typically related to the development of new products, and may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect the business.
• The company will need to raise additional capital to support its continuing operations and pursue its long-term business plan, including to complete the development and commercialization of its product candidates, if approved.
• The company is dependent on intellectual property licensed from third parties and we are currently party to in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our proprietary technologies and product candidates.
• The company is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anticorruption laws, and antimoney laundering laws and regulations.

Future Outlook

Neumora expects to continue incurring significant research and development expenses as it advances its product candidates through clinical development and seeks regulatory approval. The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next 12 months but anticipates needing additional financing in the future.

Industry Context

Neumora operates in the highly competitive and rapidly evolving biotechnology and biopharmaceutical industries, focusing on neuroscience drug development, a field with historically limited success. The company faces competition from large pharmaceutical companies, academic institutions, and other research organizations.

Comparison to Industry Standards

• It is difficult to compare Neumora's results directly to industry standards due to its unique precision neuroscience approach and specific pipeline focus.
• However, the company's increased R&D spending aligns with the industry trend of investing heavily in clinical development.
• The company's cash runway of at least 12 months is a common benchmark for biotech companies, but the need for future financing is typical given the capital-intensive nature of drug development.
• Companies like Biogen, Eli Lilly, and Roche are major players in the neuroscience space, and Neumora faces competition from their existing products and pipeline candidates.
• The success rate for neuroscience drug development is historically low, making Neumora's approach and clinical trial results critical for its long-term viability.

Legal Proceedings

• On February 6, 2025, a purported stockholder of the Company filed a lawsuit against us, certain executive officers, and certain underwriters in the United States District Court for the Southern District of New York (Case No. 1:25-cv-01072).
• The complaint is a putative class action alleging violations of the Securities Act of 1933, as amended (Securities Act) related to our initial public offering on September 15, 2023.
• The plaintiff seeks compensatory damages, as well as fees and costs.
• The complaint claims that our offering documents contained false and misleading statements and omitted material facts about the prospects of navacaprant.
• We do not believe these allegations have merit and intend to move to dismiss.

Related Party Transactions

• As of March 31, 2025 and December 31, 2024, the Company was obligated to pay Amgen $ 6.3 million and nil , respectively, under the Amgen Collaboration Agreement, which was recorded within current liabilities on the condensed consolidated balance sheets.
• During the three months ended March 31, 2025 and 2024, the Company recorded $ 6.3 million and nil , respectively, of research and development expenses with Amgen.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to market conditions and company performance.
• Employees are subject to the company's ability to secure additional funding and maintain operations.
• Patients may benefit from the development of new therapies for neuropsychiatric disorders and neurodegenerative diseases.
• Suppliers and creditors are subject to the company's ability to meet its financial obligations.

Next Steps

• Report topline data from KOASTAL-3 in Q1 2026 and KOASTAL-2 in Q2 2026.
• Report data from the Phase 1b signal-seeking study of NMRA-511 around the end of 2025.
• Progress an M4 PAM into the clinic in mid-2025.

Key Dates

Keywords

Neumora Therapeutics, financial results, clinical trials, navacaprant, NMRA-511, M4 PAM, K2 HealthVentures, research and development, net loss, biopharmaceutical